Home Tags JEWEL-101

Tag: JEWEL-101

Initial Dose-Escalation of First-in-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in...

An ongoing, phase 1 dose-escalation study investigating XB002, Exelixis’ next-generation tissue factor-targeting antibody-drug conjugate (ADC) for the treatment of patients with advanced solid tumors, has shown promising results.

X